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Sanches7, T Ruppert6, E Miyoshi8, M Pierce9, F 
Carneiro1,10,11, D Kolarich4, R Seruca 1,10, Y 
Yamaguchi3, N Taniguchi3, CA Reis 1,2,10 and SS Pinho 
1,2  
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ABSTRACT  
E-cadherin is a central molecule in the process of gastric carcinogenesis and its posttranslational 
modifications by N-glycosylation have been described to induce a deleterious effect on cell 
adhesion associated with tumor cell invasion. However, the role that site- specific glycosylation of 
E-cadherin has in its defective function in gastric cancer cells needs to be determined. Using 
transgenic mice models and human clinical samples, we demonstrated that N-
acetylglucosaminyltransferase V (GnT-V)-mediated glycosylation causes an abnormal pattern of E-
cadherin expression in the gastric mucosa. In vitro models further indicated that, among the four 
potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified 
with β1,6 GlcNAc-branched N-glycans catalyzed by GnT-V. This aberrant glycan modification on 
this specific asparagine site of E-cadherin was demonstrated to affect its critical functions in gastric 
cancer cells by affecting E-cadherin cellular localization, cis-dimer formation, molecular assembly 
and stability of the adherens junctions and cell–cell aggregation, which was further observed in 
human gastric carcinomas. Interestingly, manipulating this site-specific glycosylation, by 
preventing Asn-554 from receiving the deleterious branched structures, either by a mutation or by 
silencing GnT-V, resulted in a protective effect on E-cadherin, precluding its functional 
dysregulation and contributing to tumor suppression.  
Oncogene advance online publication, 20 July 2015; doi:10.1038/onc.2015.225  
 
INTRODUCTION  
Epithelial cadherin (E-cadherin) is a calcium-dependent cell–cell adhesion molecule with a critical 
role in epithelial tissue morphogenesis.
1–7
 The mature E-cadherin protein is organized into three 
major structural domains: an ectodomain of about 550 amino acids comprised of five tandemly 
repeated subdomains (EC1–EC5), a single transmembrane domain and a short cytoplasmic domain 
of about 150 amino acids. The human E-cadherin ectodomain is comprised of four potential N-
glycosylation sites: two putative sites located in the EC4 subdomain (Asn-554 and Asn-566) and the 
remaining two potential sites in the EC5 subdomain (Asn-618 and Asn-633).
6
  
Epithelial cell–cell adhesion is achieved through homophilic interactions between cadherin 
molecules of neighboring cells. The extracellular domains of E-cadherins on the same cell surface 
establish lateral or cis- interactions and then among adjacent cells to form trans adhesive bonds, 
leading to the formation of a zipper-like structure.
8–10
 Cell–cell adhesion is further accomplished 
through the molecular interaction of the cytoplasmic domain of E-cadherin and the catenins β-, γ-, 
α- and p120-catenin. The stability of this cadherin–catenin complex, and its interaction with the 
actin cytoskeleton, forms the core adherens junctions, which is essential for cell–cell adhesion and 
precludes individual epithelial cell motility, thus providing a normal and homeostatic tissue 
architecture.
11,12
  
The functional inactivation or downregulation of E-cadherin is considered to be a hallmark of the 
epithelial carcinogenic process, being closely associated with tumor cell invasion and metastases.
13
 
Several mechanisms have been proposed to explain the loss of function of E-cadherin in cancer,
7
 
and among those mechanisms, the modification of E-cadherin by glycosylation has been 
demonstrated to be instrumental for the regulation of E-cadherin functions in the context of 
cancer.
14,15
 Moreover, O-mannosylation of E-cadherin was recently demonstrated to be important 
for E-cadherin-mediated cell–cell adhesion.
16,17
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In fact, during malignant transformation, the glycosylation profile of E-cadherin undergoes a 
significant alteration,
18
 with implications for its biological functions. Of those glycosylation 
alterations, two are generally considered to be fundamental for the regulation of the protein: the 
bisecting GlcNAc N-glycan structures (catalyzed by the N-acetylglucosaminyltransferase III (GnT-III) 
glycosyltransferase), and the β1,6 GlcNAc-branched N-glycan structure (catalyzed by the GnT-V 
glycosyltransferase). These two key glycan structures were recently found to precisely control, in an 
opposite manner, the functions of E-cadherin in cancer cells.
15,19–24
 E-cadherin has different N-
glycosylation sites that are potentially responsible for controlling its biological functions. Under 
normal physiological circumstances, E-cadherin was described to be primarily modified with high-
mannose/hybrid N-glycans;
25,26
 however, the key site(s) that are crucial for the regulation of its 
functions in the context of cancer remain to be determined.  
In this study, we report that E-cadherin becomes functionally impaired when GnT-V 
glycosyltransferase catalyzed modification of site 1 (Asn-554) with β1,6 GlcNAc-branched N-glycan 
structures. Further, the presence of a mutation of this specific N-glycosylation site (which abrogates 
the availability of this site to be modified by GnT-V) has a protective effect on E-cadherin function, 
preventing its dysregulation.  
 
RESULTS 
Impact of GnT-V-mediated glycosylation in E-cadherin expression in the mice 
stomach and in human gastric carcinoma 
In the present study, we used GnT-V transgenic mouse models to show that differential expression 
of E-cadherin in the gastric mucosa is influenced by the presence of GnT-V. We used two transgenic 
mouse models: MGAT5 knockout (with no GnT-V activity) and MGAT5 transgenic mice that 
overexpress GnT-V activity. We observed that the gastric mucosa of the wild-type (WT) mice 
showed a moderate expression of β1,6 GlcNAc-branched structures detected by the biotinylated 
Phaseolus vulgaris leucoagglutinin (L-PHA) lectin. The gastric mucosa of the MGAT5 knockout mice 
showed no L-PHA reactivity (Figure 1a). On the other hand, mice overexpressing GnT-V showed 
high levels of expression of β1,6 GlcNAc-branched structures in the gastric mucosa. Regarding E-
cadherin localization, MGAT5 knockout mice showed E-cadherin normally expressed in the 
basolateral cell membrane of gastric epithelial cells. In GnT-V-overexpressing mice, E-cadherin was 
also displayed in the cytoplasm of cells at the neck zone and in deep glands of the gastric mucosa 
(Figure 1a). No major histopathological lesions were observed in the gastric mucosa of these mouse 
models.  
Similarly, the levels and profile of E-cadherin modifications with the aberrant β1,6-branched N-
glycans (catalyzed by GnT-V) in human gastric carcinomas (diffuse gastric cancer sub-type) and the 
correlation with prognostic features were demonstrated by performing in situ Proximity Ligation 
Assay (PLA) technique (Figure 1b). PLA is a technology that extends the capabilities of traditional 
immunoassays to include direct detection of proteins, protein interactions and posttranslational 
modifications such as glycosylation with high specificity and sensitivity.
27
 Our results showed that 
gastric carcinoma cells display a marked increase of positive PLA signals demonstrating an 
increased modification of E-cadherin with β1,6-branching N-glycans. The normal gastric mucosa 
was either negative or showed a weak PLA signal, suggesting that E-cadherin is not modified by 
GnT-V-mediated branching glycans in normal gastric cells (Figure 1b). Furthermore, and in order to 
evaluate whether the GnT-V-mediated glycosylation of E-cadherin is correlated with prognosis, a 
series of 19 patients with diffuse gastric cancer was analyzed and associated with prognostic 
variables. Patients positive for E-cadherin+β1, 6-branched N-glycans (positive PLA) display a poorer 
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survival rate (assessed by Kaplan–Meier survival analysis) when compared with diffuse gastric 
cancer patients negative for PLA E-cadherin/L-PHA (P = 0.093; Figure 1, Graphic b1). Additionally, 
we further showed that all patients who do not survive were positive for PLA E-cadherin/ L-PHA, as 
represented in Table 1 (P = 0.077).  
These results demonstrate the importance of this specific E-cadherin aberrant glycoform in vivo in 
the pathogenesis of gastric carcinoma.  
 
Bioinformatics evaluation of E-cadherin N-glycosylation site occupancy 
Glycosylation is known to be a cell- and tissue-specific event and the levels and pattern of 
glycosylation of a specific protein vary accordingly with cell and tissue location
28
 (Supplementary 
Figure S1). N-linked glycosylation does not occur at every potential glycosylation site. Depending 
on the protein and on the physiopathological context, some glycosylation sites are more important 
than others for the regulation of protein function.
29
  
Using an in silico bioinformatics analysis that takes three main criteria into consideration, E-
cadherin N-glycosylation site occupancy could be predicted. The first criterion is based on the 
species homology of the E-cadherin peptide sequence (Figure 2a). A comparison of the E-cadherin 
peptide sequence between different species revealed that the N-glycosylation sites Asn-554 (site 1) 
and Asn-633 (site 4) are the most conserved among species.  
The second criterion used in the evaluation is the site-specific modification of N-linked glycans 
through the solvent accessible surface area (ASA) calculation of four Asn residues. Very low ASA 
values at Asn residue indicate a reduced probability of N-glycans attachment. As shown in Figure 
2b, the potential N-glycosylation site Asn-618 (site 3) displays a low ASA value, suggesting a low 
probability of being N-glycosylated.  
The third criterion is the evaluation of the β-turn propensity at the Asn-x-Ser/Thr acceptor sequence 
(Figure 2c). The variable x represents the sequence position around the sequon and a high value of 
β-turn propensity at an Asn residue can positively affect the spatial configuration of Asn and 
Ser/Thr side chains towards the approach of an oligosaccharyltransferase. For x=0 (Asn residue), 
Asn-554 (site 1) and Asn-633 (site 4) show higher β-turn propensity values demonstrating a high 
probability for the occurrence of N-glycosylation. It has also been reported that the presence of Pro 
at x=3 position inhibits N-glycosylation.
30,31
 Taken these issues into account, Asn-566 (site 2) and 
Asn-618 (site 3) are not likely to be glycosylated.  
Overall, the combination of these in silico parameters (Figure 2d) suggests that N-glycosylation is 
likely to occur at Asn-554 (site 1) and Asn-633 (site 4) and not likely to occur in the other two 
putative sites (sites 2 and 3).  
 
E-cadherin Asn-554 (site 1) and Asn-633 (site 4) are occupied with complex- and high-
mannose/hybrid-type N-glycans, respectively  
In order to further characterize in vitro the E-cadherin N-glycosylation site occupancy, we applied 
site-directed mutagenesis to generate different E-cadherin N-glycan mutants lacking selected 
potential N-glycosylation sites by replacing asparagine for glutamine residues in each N-
glycosylation consensus sequence (NXS/T) either individually or in different combinations (Figure 
3a).  
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The different E-cadherin N-glycan mutants were transfected into gastric carcinoma AGS cell line 
(that lacks endogenous E-cadherin both at mRNA and protein levels
32
), and the mobility shift of the 
E-cadherin band was evaluated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS–PAGE; Figure 3b). Concerning the individual E-cadherin N-glycan mutants (M1, M2, M3 and 
M4), the results showed that the E-cadherin mutant M1 (lacking site 1, Asn-554) revealed the most 
pronounced mobility shift followed by the E-cadherin mutant M4 that displayed a slight mobility 
compared with E-cadherin WT. E-cadherin mutants M2 and M3 did not exhibit a mobility shift 
compared with the WT. These results suggest that sites 1 (Asn-554) and 4 (Asn-633) are N-
glycosylated. In addition, and consistent with the bioinformatics prediction, site 2 (Asn-566) and 
site 3 (Asn-618) are not occupied with N-glycans. Validating these observations, the multiple E-
cadherin N-glycan mutants M1234 (total N-glycan mutant) and M14 (with Asn-554 and Asn-633 not 
present) showed the same mobility shift that was slightly higher than that for E-cadherin M1. E-
cadherin M23 did not display a mobility shift compared with E-cadherin WT, further suggesting that 
sites 2 and 3 are not N-glycosylated.  
Next we determined the susceptibility of the E-cadherin N-glycan mutants towards different 
endoglycosidases, namely PNGase F and Endo H. As shown in Figure 3c, E-cadherin WT showed 
partial sensitivity to Endo H but, being predominantly PNGase F-sensitive, indicating that E-
cadherin WT is modified with both complex and high-mannose/hybrid-type N-glycans. The E-
cadherin mutant M234 showed a slight shift upon Endo H but exhibited a significant mobility shift 
after PNGase F digestion. On the other hand, treatment of M123 with Endo H resulted in a 
substantial mobility shift that was not further enhanced by PNGase F. These observations indicate 
that Asn-554 is modified mostly by complex-type structures, whereas Asn-633 appears to contain 
mainly high-mannose/hybrid-type N-glycans. This is also consistent with the higher mobility shift of 
M1 compared with M4 (Figure 3b).  
These observations were further supported by a glycomics analysis of the released N-glycans of E-
cadherin WT, M123 and M234 by porous graphitized carbon (PGC) nano-liquid chromatography–
electronspray ionization tandem mass spectrometry (nanoLC-ESI MS/MS). The respective E-
cadherin proteins were immunoprecipitated, SDS–PAGE separated and electro-blotted onto 
polyvinylidene difluoride (PVDF) membranes prior on-blot PNGase F digestion as described 
earlier.
33,34
 E-cadherin WT and M234 showed higher levels of sialylated and complex type N-glycans, 
respectively (Figure 3d). E-cadherin WT showed the highest levels of complex type, triantennary N-
glycans (Supplementary Figure S2, Supplementary Tables S1 and S2). These structures were found 
reduced in M123 and could not be detected in M234 (Supplementary Figure S2), further indicating 
the presence of tetra-antennary N-glycans in M234 (though these analyses do not allow an absolute 
glycan quantitation).  
Regarding M134, M124 and M14 (all with a mutation at sites 1 and 4), no detectable changes were 
observed after Endo H/PNGase F treatment, supporting the hypothesis that Asn-566 (site 2) and 
Asn-618 (site 3) are not N-glycosylated. As expected, E-cadherin with all potential N-glycosylation 
sites mutated (M1234) was neither Endo H nor PNGase F sensitive. Taken together (see also 
Supplementary Figure S3), these results indicate that, in gastric cancer cells, E-cadherin is modified 
with mostly complex-type N-glycans at site 1 (Asn-554) and with mainly high-mannose/hybrid-type 
at site 4 (Asn-633), whereas sites 2 and 3 (Asn-566 and Asn-618) were not N-glycosylated. A 
statistical analysis suggests that glycosylation sites carrying highly processed complex-type glycans 
are significantly more solvent-accessible than those carrying less processed high-mannose-type 
glycans.
35
 Consistent with this, ASA of Asn-633 is lower than that of Asn-554 (Figure 2b).  
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Site-specific occupancy of Asn-554 with complex type N-glycans has a deleterious 
effect on E-cadherin localization and dimerization  
The glycosylation of E-cadherin with complex-type N-glycans, such as bisecting GlcNAc and the 
β1,6 GlcNAc-branched N-glycans structures, has been reported to precisely regulate E-cadherin 
functions in an opposing manner.
15,20
 Having confirmed that site 1 (Asn-554) of E-cadherin is the 
one that is mainly occupied with complex-type N-glycans (Figure 3, Supplementary Figure S2), we 
proceeded to further evaluate the functional impact of this site-specific N-glycan occupancy by 
comparing the mutants M1 and M234, representing the absence versus the presence of a complex 
N-glycan on site 1, respectively. By immunofluorescence analysis, we evaluated the cellular 
localization of E-cadherin and cell morphology, and the results showed that AGS cells expressing 
the E-cadherin M1 mutant (Figure 4a) or M123 (Supplementary Figure S4A) exhibited a membrane 
localization of E-cadherin that showed a more focused membrane staining than the E-cadherin WT 
(as revealed by confocal microscopy). By contrast, AGS cells expressing E-cadherin M234 (or E-
cadherin M4, Supplementary Figure S4A) displayed an aberrant E-cadherin expression with mis-
localization into the cytoplasm. Quantitative analyses of in situ immunofluorescence images that 
consider internuclear profiles further showed a focused membrane localization of E-cadherin after 
mutation at Asn-554 (E-cadherin M1) and a decreased E-cadherin membrane expression in M234 
(Figure 4A1). Regarding the E-cadherin M2, M3 and M23 mutants, no alterations were observed in 
the cellular localization of E-cadherin compared with E-cadherin WT (Supplementary Figure S4A).  
We then attempted to determine whether cis-dimer formation of E-cadherin was affected by the 
occupancy/mutation of site 1 with complex-type N-glycans, by performing a cis-dimerization assay 
using BS
3
, a membrane-impermeable chemical cross-linker. The formation of E-cadherin cis-dimers 
was observed after AGS cells expressing E-cadherin WT, M1 or M234 were treated with BS
3 
(Figure 
4b). However, the levels of E-cadherin cis-dimerization were significantly higher in E-cadherin M1 
than in E-cadherin WT and M234 (Figure 4B1) or than in M4 (Supplementary Figures S4B and B1), 
indicating that the mutation of Asn-554 (M1) enhanced the formation of E-cadherin 
cis
-dimers.  
In addition, a calcium switch assay was performed (Supplementary Figure S5). These results 
showed that the calcium-binding property appear to be independent of E-cadherin glycosylation; 
however, it is observed that E-cadherin M234 showed a more evident impact in the calcium-binding 
property of E-cadherin.  
Consistent with this, the deletion of site 1 (M1) induced a significantly increased rate of cell–cell 
adhesion together with the formation of larger compact cellular aggregates when compared with E-
cadherin WT and M234 (Figures 4c and c1; Supplementary Figure S4C).  
 
Site-specific occupancy of Asn-554 with complex-type N-glycans impairs a competent 
adhesion complex formation  
We further evaluated whether the mutation of Asn-554 and/or the occupancy of this specific N-
glycan site could affect the molecular organization and assembly of the cadherin–catenin complex. 
No significant differences were observed in the total expression levels of the catenins, β- and p120-
catenin, among the different E-cadherin N-glycan mutants (Figure 4d). However, an increased E-
cadherin/β-catenin interaction was verified in E-cadherin M1 in comparison with E-cadherin WT 
(0.7-fold) and a significantly decreased interaction was found between E-cadherin and β-catenin 
when Asn-554 (site 1) was N-glycosylated (M234 or M4, Figures 4e and e1; Supplementary Figures 
4D and D1). In addition, we verified a 1.3- and 0.9-fold increased interaction between E-cadherin 
and p-120-catenin when Asn-554 (site 1) was mutated (M1) when compared with E-cadherin WT 
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and E-cadherin M234, respectively, suggesting that mutation of site 1 resulted in an increased 
recruitment of catenins by E-cadherin (Figures 4e and e1). These differences in the recruitment of 
catenins by E-cadherin reflect the positive impact on the assembly and stability of the cadherin–
catenin complex induced by the mutagenesis of Asn-554 (site 1).  
 
 
 
Preventing Asn-554 site-specific glycosylation improves E-cadherin functions  
Having demonstrated the deleterious effects of site 1 N-glycan occupancy for the biological 
functions of E-cadherin in gastric tumor cells (Figure 4), we further identified the specific type of 
complex N-glycans that are attached to Asn-554. Figure 5a demonstrates that E-cadherin M234 
showed an increased reactivity with the L-PHA lectin compared with M1, which is indicative of the 
presence of β1,6 GlcNAc-branched structures at Asn-554 (site 1). Both E-cadherin WT and M234 
show similar β1,6 GlcNAc-branched expression patterns, as both retain the Asn-554 complex 
glycan. In contrast, no positive reactivity with L-PHA on the E-cadherin band in the M1 mutant was 
observed, showing that site 1 is specifically modified with β1,6 GlcNAc-branched structures. Despite 
that it was not possible to unambiguously substantiate the β1,6 GlcNAc nature of the branching in 
M234 with the minimal amounts of E-cadherin material available for glycomic analyses, the 
triantennary N-glycans were only detected in E-cadherin WT and M123 and not in M234. 
Nevertheless, the combined data presented here clearly indicate that also a subtle increase of a 
specific structure feature on E-cadherin induces a strong functional response.  
To confirm these results, we performed silencing of the MGAT5 gene using the small interfering 
RNA (siRNA) technique (Figure 5b). As shown in Figure 5c, the knockdown of GnT-V resulted in a 
significant decrease in the expression of β1,6 GlcNAc-branched structures (decreased L-PHA 
reactivity) in total cell lysates compared with non-silenced (NS) cells. The decreased L-PHA 
reactivity was also observed in total cell lysates of AGS Mock siRNA cells when compared with NS 
cells (Supplementary Figure S6). As a consequence of the GnT-V knockdown, we observed a 
competitive increase in the expression of bisecting GlcNAc structures (increased biotinylated 
Phaseolus vulgaris erythroagglutinin (E-PHA) reactivity) in the total cell lysates of the GnT-V 
knockdown cells compared with NS cells, as previously described. The silencing of MGAT5 led to a 
decrease in the reactivity of E-cadherin M234 with the L-PHA lectin compared with the control (NS), 
which further supports the conclusion that site 1 is specifically modified with β1,6 GlcNAc-branched 
structures catalyzed by GnT-V enzymatic activity (Figure 5d). Furthermore, our results showed that, 
upon MGAT5 knockdown, the gastric tumor cells expressing E-cadherin M234+siGnT-V displayed a 
notable change of its pattern of expression, showing a decreased cytoplasmic staining and an 
increase in membrane expression compared with NS cells (Figure 5e). In addition, we also 
demonstrated that, after the knockdown of GnT-V, the ratio of E-cadherin cis-dimers in gastric 
tumor cells expressing E-cadherin M234+siGnT-V increased to levels similar to that for E-cadherin 
M1 (Figures 5f and f1), suggesting that the inhibition of GnT-V- mediated modification with β1,6 
GlcNAc-branched structures at Asn-554 (site 1) induces increased E-cadherin cis-dimer formation 
and, consequently, the strengthening of cell–cell adhesion.  
These results reveal that the GnT-V selectively modifies N-glycosylation site 1 (Asn-554) on E-
cadherin in the context of gastric tumor cells and that its silencing clearly increases E-cadherin-
mediated cell–cell adhesion and expression.  
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DISCUSSION 
In the present study, using two different MGAT5 mouse models, we showed that the pattern of E-
cadherin expression in gastric mucosa cells depends on the presence of β1,6 GlcNAc-branched N-
glycans that are formed as the result of enzymatic catalysis by GnT-V (MGAT5). MGAT5 transgenic 
mice (which overexpress GnT- V-mediated glycosylation) display an abnormal pattern of E-cadherin 
cellular expression in gastric epithelial cells that overexpress β1,6 GlcNAc-branched N-glycans 
compared with MGAT5 knockout mice (with absence GnT-V-mediated enzymatic activity). 
Additionally, we verified that human diffuse gastric carcinoma is characterized by an aberrant 
pattern of E-cadherin N-glycosylation mediated by GnT-V. Moreover, we observed that diffuse 
gastric cancer patients displaying an aberrant glycosylation of E-cadherin mediated by GnT-V tend 
to exhibit a poorer survival rate when compared with gastric cancer patients without GnT-V-
mediated glycosylation on E-cadherin.  
We further investigated the specific N-glycosylation site(s) that are required for controlling E-
cadherin functions in gastric cancer, particularly the key E-cadherin N-glycosylation site that can be 
modified with the deleterious β1,6 GlcNAc-branched structures catalyzed by the action of the GnT-
V glycosyltransferase. Through combination of bioinformatics prediction tools with mutagenesis 
and glycans enzymatic digestion approaches as well as glycomic analyses, our results consistently 
revealed that, among the four potential N-glycosylation sites available in the extracellular domain 
of E-cadherin, Asn-554 (site 1) and Asn-633 (site 4) are N-glycosylated, respectively, with complex-
type and high-mannose N-glycans structures. Conversely, Asn-566 (site 2) and Asn-618 (site 3) of E-
cadherin are not occupied with N-glycans, suggesting that these N-glycosylation sites are not 
critical for controlling the biological functions of E-cadherin in gastric tumor cells. Consistent with 
our observations, previous reports have shown that E-cadherin from a CHO cell line is modified with 
N-glycans at Asn-554 and Asn-633
ref
. 
36
 and that Asn-633 is modified with high-mannose N-glycans 
that were demonstrated to be important for the folding of E-cadherin.14 In addition, our glycomics 
data showed that E-cadherin WT carries triantennary, sialylated N-glycans, whereas the 
glycosylation was found to be altered on the M123 and M234 mutants. These data indicate that site-
specific mutations of the N-glycosylation sites on E-cadherin appear to alter the protein 
conformation and thus also the accessibility for the glycosyltransferases required for the formation 
of described N-glycans.  
We clearly demonstrated that site 1 (Asn-554) in the extracellular domain of E-cadherin is the 
selected site modified with the β1,6 GlcNAc-branched structures and the key site for the functional 
regulation of E-cadherin in gastric tumor cells. Whenever site 1 (Asn-554) is modified with β1,6 
GlcNAc- branched structures, the localization and functions of E-cadherin are impaired (Figure 6) 
by: compromising its cis-dimerization capability, by decreasing the rate of cell–cell aggregation, 
and also by interfering in the molecular assembly and stability of the adhesion complex, that 
altogether promotes its cellular mis-localization and non-functional role. In fact, a mutation of this 
specific site 1 (E-cadherin M1 or M123) resulted in a protective effect, precluding the functional 
impairment of E-cadherin through the recovery of E-cadherin-mediated cell–cell adhesion, an 
increased stability of adherens junctions and the correct membrane localization of the molecule. 
Similarly, the silencing of the MGAT5 gene that encodes GnT-V also resulted in a restoration of E-
cadherin expression and functions. Although the GnT-V knockdown is likely to affect various cell 
surface receptors, in this study we focused on E-cadherin, showing that upon GnT-V knockdown, 
the E-cadherin N-glycan mutant M234 (in which site 1 is available) loses the β1,6 GlcNAc-branched 
structures and consequently has increased cis-dimerization capability, increases recruitment of 
catenins and, importantly, it reaches the cell membrane, behaving similar to the M1 mutant. These 
results on M234 (and M4) mutant also suggest that loss of high-mannose glycan in site 4 may also 
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contribute to this process, as it was previously shown the importance of this site for E-cadherin 
folding.
14
 Therefore, blocking Asn-554 (site 1), either by mutation or by GnT-V silencing, resulted in 
a protective effect on E-cadherin to not become aberrantly glycosylated thus avoiding its functional 
dysregulation (Figure 6). Taken together, these observations are in agreement with the results 
using transgenic mice regarding an E-cadherin phenotype where the MGAT5 knockout resembles 
the M1 mutant and the M234+siGnT-V, whereas the GnT-V overexpressing mice are parallel with 
the M234 or M4 mutant. Furthermore and importantly from the clinical standpoint, we showed that 
gastric cancer patients with poor prognosis displayed a marked increased modification of E-
cadherin with β1,6-branching N-glycans highlighting the importance of this specific E-cadherin 
aberrant glycoform in the gastric carcinogenic process.  
Overall, this is the first study to clearly demonstrate that, among the four putative N-glycosylation 
sites, site 1 (Asn-554) in the EC4 domain of E-cadherin is the one that is selectively modified by the 
GnT-V glycosyltransferase in gastric carcinoma cells leading to its functional impairment. The 
molecular mechanism governing the specific biosynthesis of the β1,6 GlcNAc-branched structures 
at site 1 of E-cadherin, and not on any of the other three sites, remains unknown. Nevertheless, it is 
possible that, because this N-glycosylation site is the most extracellular (the furthest from the 
membrane), it is therefore more likely to regulate adhesion with neighboring cells. Additionally, the 
pathological context of gastric tumor cells may also account for this selective remodeling of E-
cadherin N-glycosylation site 1 by GnT-V, which probably occurs depending on the 
physiopathological context and in a tissue- and cell-specific manner.
19,37–39
  
Taken together, we discover how site-specific E-cadherin glycosylation modification can directly 
modulate E-cadherin-mediated cell–cell adhesion, a key pathophysiological event in cancer 
progression. Moreover, preventing E-cadherin site-specific glycosylation modifications was shown 
to improve its tumor-suppressive functions in gastric cancer. These results may open new avenues 
for the discovery of a promising (glyco)biomarker for improving early diagnosis, clinical surveillance 
and patients' risk stratification, as well as for the development of targeted-specific therapeutic 
strategies applied to the clinical setting.  
 
MATERIALS 
Tissue immunohistochemistry  
Formalin-fixed paraffin-embedded tissue from normal, MGAT5 knockout (C57BL/6 background; 
generously provided by Professor Michael Pierce) and MGAT5 transgenic mouse stomach (C57BL/6 
background; generously provided by Professor Eiji Miyoshi) were used for E-cadherin and L-PHA 
staining as previously described.
15
  
 
In situ PLA 
A series of human stomach samples from both normal mucosa (n = 4) and gastric carcinoma diffuse-
type (n=19) were obtained from the S. João Centre Hospital, Porto, Portugal and subjected to in situ 
PLA.
27
 This study was approved by the committee of S. João Centre Hospital. An informed consent 
was obtained for all the following subjects.  
An antibody against E-cadherin (Mouse anti-E-cadherin, clone 4A2C7) and L-PHA biotinylated 
lectin against the β1,6 GlcNAc-branched N-glycan structure (Vector Laboratories, Burlingame, CA, 
USA) were used. The PLA probes used were, respectively, anti-mouse immunoglobulins PLUS and 
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anti-biotin-MINUS, conjugated to oligonucleotides. Images were acquired using brightfield and/or 
fluorescence microscope. The PLA signal was evaluated by three independent observers and scored 
as follows: negative, when absent/low expression of PLA signal was observed; and positive, when 
moderate/high expression of PLA signal was observed.  
 
Prediction of N-glycosylation site occupancy 
Amino-acid sequences of E-cadherin from various species are extracted from NCBI Reference 
Sequences
40 
and selected by means of BLAST search.
41
 Multiple top-hit sequences are aligned using 
Clustal W.
42
 3D homology modeling of E-cadherin was performed using the MODELLER version 9.8 
software (San Francisco, CA, USA).
43
 The crystal structures of the N-terminal domain of human E-
cadherin (PDB ID 1o6s) and C-cadherin ectodomain (PDB ID 1l3w) were used as templates. The 
solvent ASA of the model was calculated using the DSSP program (San Franscisco, CA, USA).
44
 A 
sliding window method was used to calculate the averaged ASA (window size=5), and the value was 
assigned to the central amino-acid residue. The β-turn propensity was predicted by the Chou 
Fasman method
45
 using updated PDB data.
46
  
 
Plasmids construction and site-directed mutagenesis 
A plasmid pcDNA3-E-cad containing human full-length E-cadherin cDNA (GenBank accession no. 
Z13009) was used to produce the E-cadherin N-glycan site mutations singly and in different 
combinations. PCR-based site-directed mutagenesis was carried out using the QuickChange XL 
Site-directed Mutagenesis Kit (Stratagene, Santa Clara, CA, USA). The mutagenesis primers used to 
the replacement of asparagine for glutamine in the potential N-glycosylation sites (Asn-554, Asn-
566, Asn-618 and Asn- 633) were created according to the manufacturer's instructions. All 
mutations were confirmed by DNA sequencing.  
 
Release of N- and O-glycans and nanoPGC LC-ESI-MS/MS analysis 
The N-glycans of immunoprecipitated E-cadherin WT and the respective mutants were released 
from PVDF membranes after SDS–PAGE separation and electro-blotting onto PVDF membranes to 
immobilize glycoproteins as described previously.
34,35
 The released N-glycans were dissolved in 10 
μl of pure water, and 5 μl were injected and analyzed by PGC nanoLC-ESI-MS/MS (Ultimate 3000 
UHPLC system, Dionex, Sunnyvale, CA, USA) coupled to an amaZon ETD Speed ion trap equipped 
with a CaptiveSpray ionization source in negative ion mode (all Bruker Daltonics, Bremen, 
Germany). The instrument was set up to perform collision-induced dissociation fragmentation. An 
m/z range from 380 to 1850Da was used for data-dependent precursor scanning with the SPS target 
mass set to 900 m/z. The capillary voltage was set at 1.3 kV, and the three most intense signals were 
selected for collision-induced dissociation experiments (MS/MS scan range 50–2500m/z). MS as well 
as MS/MS data were recorded in the instrument's 'ultra scan mode'. Glycans were loaded onto a 
PGC precolumn (Hypercarb KAPPA 30 × 0.32 mm, 5 μm particle size) and separated on an analytical 
PGC column (Hypercarb PGC Column, Thermo, 100 mm × 75 μm, 3 μm particle size, both Thermo 
Fisher, Waltham, MA, USA). The samples were loaded onto the precolumn at a flow rate of 6 μl/min 
in 100% buffer A (10mM ammonium bicarbonate). The starting conditions for the analytical column 
were 2% buffer B (10 mM ammonium bicarbonate in 60% acetonitrile) at a flow rate of 0.8μl/min. 
The gradient conditions were as follows: increase of buffer B from 3% to 15.8% (6 min), further 
increase to 40.3% B (6–55 min), followed by a steeper increase to 90% B (55–60 min). The column 
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was held at 90% B for 6 min. At the same time, the precolumn was flushed with 90% Buffer C 
(10mM ammonium bicarbonate in 90% acetonitrile) at a flow rate of 6μl/min before re- 
equilibrating the precolumn as well as the analytical column in 98% buffer A for 5min. Glycans were 
automatically identified using an in-house established N-glycan spectral database and the spectral 
library tool integrated in Compass Data Analysis 4.1 (Bruker Daltonics). N-glycan structures not 
present in the database were assigned manually if sufficient data could be acquired. If no 
unambiguous identification of a structure was possible based on the MS/MS and LC data but just on 
MS data only, the respective portion of the N-glycan is labeled accordingly in the Supplementary 
Tables S1 and S2. Glycan compositions were determined using the GlycoMod tool available on the 
ExPASy server
47
 (http://web. expasy.org/glycomod/; with a mass tolerance of 0.3 Da in the negative 
ion mode, reduced N-glycan oligosaccharides, respectively, and restricted to the monosaccharide 
residues hexose (Hex), N-acetyl hexosamine (HexNAc), deoxyhexose, N-acetyl neuraminic acid 
(NeuAc), N-glycolyl neuraminic acid (NeuGc) and sulfate.  
The accessed glycan structures were then manually validated from tandem MS fragmentation 
spectra using the Glycoworkbench software tool (Eurocarb, Cambridge, UK).
48
 Data reporting has 
been performed as proposed by the MIRAGE guidelines.
49,50
  
 
Data processing and relative quantitation of PGC glycomics data  
The peak area of each glycan composition and isoform was calculated using the respective 
extracted ion chromatograms using Compass QuantAnalysis (Bruker Daltonics). The integration of 
every extracted ion chromatogram was validated manually, in particular for peaks with very low 
abundance. The generated data were imported in CSV format, converted in Excel (Microsoft Office 
Excel 2013, Redmond, WA, USA) and expressed as a relative abundance value for each individual N-
glycan structure, respectively, within each E-cadherin type. The N-glycans were classified into three 
categories (high mannose, neutral or sialylated).  
 
Cell culture and transfection 
MDCK (Madin Darby canine kidney), BT20 (breast tumor cell line), HT29 (human colon cancer cell 
line) and AGS cells (human adenocarcinoma epithelial cell line) were grown in monolayer culture 
and maintained at 37°C in an atmosphere of 5% CO2 in RPMI 1640 GlutaMAX (or Dulbecco’s 
modified Eagle’s medium for BT20 cells), HEPES medium (Invitrogen, Paisley, UK) supplemented 
with 10% fetal bovine serum (Gibco, Invitrogen) and 1% penicillin–streptomycin (Gibco, Invitrogen). 
These cells were obtained from American Type Culture Collection (Manassas, VA, USA), which were 
tested and authenticated by the cell bank using their standard short tandem repeats–based 
techniques. Cells were also monitored by microscopy to maintain their original morphology and 
also tested for mycoplasma contamination.  
Cells were transfected at 40–50% confluence with E-cadherin WT and E-cadherin N-glycan mutants 
using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions.  
 
Westerns blotting, lectin blotting and immunoprecipitation 
Cell protein lysates from different E-cadherin N-glycan mutants were subjected to 7.5% SDS–PAGE 
electrophoresis, transferred to nitrocellulose membranes and probed with the primary antibody 
against E-cadherin, β-catenin, p120-catenin and tubulin, as previously described.
15
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The expression of β1,6 GlcNAc-branched N-glycan structures and the bisecting GlcNAc N-glycans 
were detected by lectin blotting analysis, where membranes were incubated, respectively, with L-
PHA (that specifically recognizes β1,6 GlcNAc-branched N-glycans, product of GnT-V) and E-PHA 
(that specifically recognizes bisecting GlcNAc N-glycans, product of GnT-III) lectins (1μg/ml; Vector 
Laboratories).
15
 For the β1,6 GlcNAc-branched N-glycans analysis on E-cadherin 
immunoprecipitated, equal amounts of total protein (750–1500 μg) from each cell lysate were used 
and the membranes were probed with L-PHA lectin.
15  
 
 
 
PNGase F and Endo H digestion 
Total cell lysates (30μg) were combined with denaturating buffer and incubated at 100 °C for 10 
min. Samples were then digested for 3 h with 1 unit of PNGase F or Endo H (New England Biolabs, 
Hertfordshire, UK) at 37 °C. Endo H is an endoglycosidase that cleaves within the chitobiose core of 
high mannose and some hybrid oligosaccharide structures in N-linked glycoproteins. PNGase F is an 
amidase that cleaves between the innermost GlcNAc and asparagine residues of high-mannose, 
hybrid and complex oligosaccharides from N-linked glycoproteins. The deglycosylated proteins 
were loaded onto 7.5% SDS–PAGE and immunoblotting with anti-E-cadherin. For controls, the 
samples were incubated without the enzymes.  
Calcium switch 
AGS expressing E-cadherin WT, M1 and M234 were washed with phosphate-buffered saline (PBS), 
incubated with EGTA 2 mM for 10 min and supplemented with medium. Cells were then lysed after 
2, 4 and 24 h with buffer containing PBS, 1% Triton X-100 and 1% NP40, and 30 μg of total cell 
lysate were subjected to 7.5% SDS–PAGE.  
 
E-cadherin cis-dimer formation 
Cells were plated in six-well plates to confluence. They were washed with PBS and incubated with 
2.5 mM BS3 (Sigma, St Louis, MO, USA) for 3h on ice. The resulting cells were then incubated with 
10mM Tris (pH 7.5) for 15 min on ice. Cells were then lysed with buffer containing PBS, 1% Triton X-
100 and 1% NP40, and 30 μg of total cell lysate were subjected to 6% SDS–PAGE. E-cadherin cis-
dimer formation was detected by immunoblotting.  
 
Immunofluorescence 
AGS cells transfected with the different E-cadherin N-glycans mutants were plated on six-well 
plates with coverslips. Cells were fixed with methanol and blocked with bovine serum albumin 5% in 
PBS. Cells were incubated with mouse anti-E-cadherin monoclonal antibody.
15
 Immunofluorescent 
images were obtained using a Zeiss Imager.Z1 AxioCam MRm (Carl Zeiss, Jena, Germany).  
For the quantitative analyses of in situ immunofluorescence images, a 1D (one dimension) 
representative profile of protein level of expression and distribution was obtained. To undertake 
this analysis, original immunofluorescence images from cell populations were used to extract 
internuclear profile map from single cells and pairs of cells.
51
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Slow-aggregation assay 
AGS cells transfected with E-cadherin WT and the different E-cadherin N-glycan mutants (5 × 104) 
were seeded onto an agar gel (0.66% w/v) in a 96-well plate. Aggregation formation was evaluated 
after 24 h using inverted phase-contrast microscope. Experiments were carried out in triplicate.  
 
siRNA transfection 
siRNA targeting MGAT5 and control siRNA were purchased from Dharmacon (Lafayette, CO, USA). 
siMGAT5 (0–200nM) was transfected into AGS cells expressing Mock, E-cadherin WT, M1 and M234 
with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Efficiency of 
MGAT5 knockdown was optimal with 80 nM of siRNA after 48 h.  
 
Statistical analysis 
PLA analyses were performed using the SPSS statistical software (IBM, Armonk, NY, USA). 
Statistical associations between clinicopathological features and aberrant E-cadherin N-
glycosylation mediated by GnT-V were assessed using the χ
2
 test. Survival curves were estimated 
using the Kaplan–Meier method.  
Statistical analyses were performed using the Graph Pad program (GraphPad Software, Inc., La 
Jolla, CA, USA). Student’s tests were used to calculate significance in an interval of 95% confidence 
level. All statistics were compared with the E-cadherin WT group, and values of P < 0.05 were 
considered to be statistically significant (Student's t-test: 
*
P ⩽ 0.05; **P ⩽ 0.01; ***P ⩽ 0.001).  
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Figure 1. Evaluation of the expression of E-cadherin and β1,6 GlcNAc-branched structures in the gastric mucosa 
of MGAT5 knockout and MGAT5 overexpressing and in human normal gastric mucosa versus gastric carcinoma. 
(a) L-PHA histochemistry detecting the β1,6 GlcNAc- branched N-glycans catalyzed by GnT-V showed a 
moderate expression of the β1,6-branched structures in the gastric mucosa of WT mice. No positive L-PHA 
reactivity was observed in the gastric mucosa of MGAT5 KO mice, whereas a clear overexpression of β1,6 
GlcNAc-branched structures was detected in MGAT5 transgenic gastric mucosa. MGAT5 KO mice showed a 
normal E-cadherin expression at the basolateral cell surface (arrowhead). In MGAT5 transgenic mice, 
immunoexpression of E-cadherin was displayed aberrantly in the cytoplasm of mucous neck cells (not shown) 
and in deep glands of the gastric mucosa (arrow). (b) In situ PLA showed weak/absence PLA signal in normal 
gastric mucosa and a marked positivity of PLA signal (brown dots for brightfield and red dots for 
immunofluorescence) in neoplastic cells from gastric carcinoma, demonstrating a profound modification of E-
cadherin with the β1,6 GlcNAc-branched structures in human gastric cancer (×40, original magnification). (b1) 
Survival rates of patients with diffuse gastric cancer (DGC) accordingly with PLA signal (positive versus 
negative). Kaplan–Meier curves demonstrate the probability of overall survival for patients with DGC 
accordingly with the presence/absence of GnT-V-mediated aberrant glycosylation of E-cadherin (P = 0.093).  
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Figure 2. Prediction of E-cadherin N-glycan site occupancy based on bioinformatics. (a) Species homology of the 
E-cadherin peptide sequence. The potential N-glycosylation sites Asn-554 and Asn-633 are well conserved. (b) 
Calculation of ASA of the four Asn residues. The potential N-glycosylation site Asn-618 displays a low ASA value. 
(c) Evaluation of β-turn propensity of the region adjacent to the Asn-X-Ser/Thr acceptor sequence. Horizontal 
axis (x) indicates sequence position around the sequon (x=0: Asn), and vertical axis (y) shows the β-turn 
propensity. For x = 0, high values of β-turn propensity mean high possibility for N-glycosylation to occur. (d) 
Prediction of E-cadherin N-glycan's occupancy. Asn-554 and Asn-633 are the two putative N-glycosylation sites 
more likely to be occupied.  
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Figure 3. N-glycosylation sites Asn-554 and Asn-633 are N-glycosylated being occupied with complex-type N-
glycans and high-mannose/hybrid- type N-glycans, respectively. (a) Schematic representation of different E-
cadherin N-glycan mutants lacking selected putative N-glycosylation sites by replacing asparagine residue with 
glutamine in each N-glycosylation consensus sequence (NXS/T) either individually or in different combinations. 
EC4, subdomain EC4; EC5, subdomain EC5; CD, cytoplasmic domain; E-cadherin WT, E-cadherin wild type; E-
cadherin M1, lacking Asn-554; M2, lacking Asn-566; M3, lacking Asn-618; M4, lacking Asn-633; M14, lacking Asn-
554 and Asn-633; M23, lacking Asn-566 and Asn-618; M234, lacking Asn-566, Asn-618, and Asn-633; M123, 
lacking Asn-554, Asn-566, Asn-618; M1234, lacking Asn-554, Asn-566, Asn-618, and Asn-633. (b) Evaluation of 
the mobility shift of E-cadherin N-glycan mutants in AGS cells compared with WT. E-cadherin N-glycan mutant 
M1 and M4 showed an increased mobility compared with E-cadherin WT. No detectable changes were observed 
regarding cadherin M2 and M3. E-cadherin M1 (arrowhead) displayed a higher mobility shift than E-cadherin M4 
(arrow). (c) Characterization of N-glycosylation profile of E-cadherin N-glycan mutants in AGS cells. Total cell 
lysates from selected transfectants were treated with Endo H and PNGase F and analyzed for mobility shifts by 
western blotting. E-cadherin WT was sensitive to Endo H (arrowhead) and PNGase F (arrow) being modified 
with high-mannose-, hybrid- and complex-type N-glycans. E-cadherin M234 was mostly sensitive to PNGase F 
(arrow) and resistant to Endo H while E-cadherin M123 was predominantly Endo H-sensitive (arrowhead). See 
also Supplementary Figure S3. (d) N-glycomics analysis using PGC nanoLC ESI MS/MS analyses showed E-
cadherin WT to carry high-mannose, complex neutral and complex sialylated N-glycans in similar amounts. E-
cadherin WT and M234 showed higher levels of sialylated and complex-type N-glycans, respectively. The data 
presented is referred to one biological replicate, which according to the well-established methodology, can be 
considered reproducible and significant. See also Supplementary Figure S2 and Supplementary Tables S1 and 
S2.  
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Figure 4. N-glycosylation at Asn-554 affects E-cadherin biological functions. (a) Immunofluorescence analysis 
showing that AGS cells expressing E-cadherin WT displayed an epithelial morphology and a membrane 
localization of E-cadherin (arrowhead). E-cadherin M1 showed a correct localization of E-cadherin at the cell 
membrane (arrowhead) with a more focused membrane staining than the WT (confocal microscopy). N-glycan 
mutant with Asn-554 (site 1) occupied with N-glycan structures (M234) is characterized by an incomplete 
localization of E-cadherin at the cell–cell contacts together with some cytoplasmic staining (arrow). White size 
bars ~5μm. (a1) Evaluation of the internuclear profiles of E-cadherin M1 and E-cadherin M234. Mutation at site 1 
(E-cadherin M1) induces an increased membrane localization of E-cadherin compared with M234, which shows a 
decreased E-cadherin membrane expression. (b) Evaluation of cis-dimer-formation capacity of E-cadherin using 
BS3. Mutation of Asn-554 (M1) leads to a significant increase of cis-dimerization of E-cadherin. (b1) Bar graphs. 
Amounts of E-cadherin cis-dimer were determined from the ratio of densities of E-cadherin cis-dimer/E-cadherin 
monomer. Results are described as mean ± s. d. of three independent experiments. The E-cadherin cis-dimer 
formation in E-cadherin M1 and M234 are expressed as the fold increase, compared with the E-cadherin WT, 
which was taken as 1 (Student's t-test: *P ⩽ 0.05; **P ⩽ 0.01; ***P ⩽ 0.001). (c) In vitro cell–cell aggregation assay. 
Mutation at Asn-554 (M1) resulted in a significant increase of cell–cell aggregation than E-cadherin WT and 
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M234 showing larger cell aggregates. (c1) Bar graphs. Quantification of cell–cell aggregation by measuring the 
relative number of cells per aggregate (three or more cells). Results are described as the mean ± s.d. of three 
independent experiments. Student's t-test: *P ⩽ 0.05; **P ⩽ 0.01; ***P ⩽ 0.001). (d) Evaluation of the β- and 
p120-catenin total protein expression levels in the total protein lysates from AGS Mock, AGS E-cadherin WT and 
E-cadherin N-glycan mutants M1 and M234 cells. No significant differences were observed among the E-
cadherin WT and E-cadherin N-glycan mutants. (e) E-cadherin immunoprecipitation followed by β- and p120-
catenin Western-blot. The results showed that mutation of site 1 (Asn-554), M1, is associated with an increased 
interaction between E-cadherin and the β- and p120-catenin. A decreased interaction between E-cadherin and 
β-catenin (of about 1.0-fold) in M234 mutant compared with E-cadherin M1 was also verified. (e1) Bar graphs. 
Amounts of association were determined from the ratios of densities of β- or p120-catenin after normalization 
to E-cadherin. Results are described as mean ± s.d. of three independent experiments. The E-cadherin/catenin 
interaction levels in E-cadherin M1 and M234 are expressed as the fold increase, compared with E-cadherin WT, 
which was considered as 1 (Student's t-test: *P ⩽ 0.05; **P ⩽ 0.01; ***P ⩽ 0.001). See also Supplementary Figure 
S4.  
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Figure 5. Knockdown of GnT-V induces the recovery of E-cadherin expression and functions. (a) 
Immunoprecipitation of E-cadherin M234 showed an increased L-PHA reactivity compared with the M1 mutant, 
revealing a significant increase in β1,6 GlcNAc-branched N-glycan structures modification in comparison with E-
cadherin M1. (b) MGAT5 mRNA expression of AGS cells expressing E-cadherin WT, M1 and M234 after MGAT5 
silencing. Around 70–80% of MGAT5 silencing was observed in WT, M1 and M234 mutants. NS, non-silencing. 
The relative mRNA expression of siRNA cells expressing E-cadherin WT, M1 and M234 are expressed as the fold 
increase, compared with the respective non- silencing cells, which was taken as 1 (Student's t-test: *P ⩽ 0.05; **P 
⩽ 0.01; ***P ⩽ 0.001). (c) Lectin blot analysis of GnT-V and GnT-III products on total cell lysate from AGS cells 
expressing E-cadherin WT, M1 and M234 after MGAT5 knockdown. A decreased L-PHA reactivity after MGAT5 
knockdown and a competitive increase of E-PHA reactivity were observed. (d) MGAT5 silencing resulted in a 
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remarkable decreased L-PHA reactivity for the E-cadherin band from the E-cadherin WT and E-cadherin M234, 
suggesting that Asn-554 is occupied with β1,6 GlcNAc- branched N-glycans. (e) Immunofluorescence analysis of 
AGS cells expressing E-cadherin WT, M1 and M234 after MGAT5 knockdown. After MGAT5 silencing, E-cadherin 
M234 showed an increased localization at the cell–cell membrane. White size bars ~ 5 μm. (f) Evaluation of the 
impact of MGAT5 silencing on cis-dimer formation of E-cadherin. Knockdown of MGAT5 leads to a similar ratio 
of E-cadherin cis-dimer formation in AGS cells expressing E-cadherin M1 and M234. (f1) Bar graphs. Amounts of 
E-cadherin cis-dimer were determined from the ratio of densities of E-cadherin cis-dimer/E-cadherin monomer. 
Results are reported as the mean ± s.d. of two independent experiment. See also Supplementary Figure S6.  
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Figure 6. Proposing model for the site-specific E-cadherin N-glycosylation in cancer context. The site-specific 
occupancy of E-cadherin Asn-554 with β1, 6 GlcNAc-branched structures catalyzed by GnT-V impairs its 
biological functions leading to a decreased E-cadherin cis-dimerization capability, a decreased cellular 
aggregation and an impairment of the molecular assembly of adherens junctions. Locking this site-specific 
modification either by Asn-554 mutation or by GnT-V silencing recovers the biological functions of E-cadherin 
by increasing E-cadherin cis-dimerization, aggregation and the stability of the E-cadherin–catenin complex.  
 
